alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S UNAUDITED FINANCIAL STATEMENTS AS OF AND FOR THE PERIOD ENDING OCT 2,
1999, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                           JAN-1-2000
<PERIOD-END>                                OCT-2-1999
<CASH>                                          25,063
<SECURITIES>                                         0
<RECEIVABLES>                                  120,115
<ALLOWANCES>                                       501
<INVENTORY>                                    340,911
<CURRENT-ASSETS>                               551,984
<PP&E>                                         311,651
<DEPRECIATION>                                  89,031
<TOTAL-ASSETS>                               1,285,425
<CURRENT-LIABILITIES>                          527,411
<BONDS>                                        224,950
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        47,752
<OTHER-SE>                                     394,877
<TOTAL-LIABILITY-AND-EQUITY>                 1,285,425
<SALES>                                      1,920,411
<TOTAL-REVENUES>                             1,920,411
<CGS>                                        1,583,737
<TOTAL-COSTS>                                1,583,737
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              20,629
<INCOME-PRETAX>                                 72,858
<INCOME-TAX>                                    28,400
<INCOME-CONTINUING>                             44,458
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    44,458
<EPS-BASIC>                                        .92
<EPS-DILUTED>                                      .90


</TABLE>
§ 346.16 Analgesic, anesthetic, and antipruritic active ingredients. The active ingredient of the product consists of any of the following when used within the concentration range established for each ingredient: ( a ) Camphor 0.1 to 3 percent.
( b ) Juniper tar 1 to 5 percent.
( c ) Menthol 0.1 to 1 percent.
### Ground water in the Eola-Amity Hills area, northern Willamette Valley, Oregon

By: Don Price

                            https://doi.org/10.3133/wsp1847

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Editorial Note on Part 179
Editorial Note: Nomenclature changes to part 179 appear at 70 FR 72074, Dec. 1, 2005.

§ 179.43 Carbon dioxide laser for etching food. Carbon dioxide laser light may be safely used for etching information on the surface of food under the following conditions: ( a ) The radiation source consists of a carbon dioxide laser designed to emit pulsed infrared radiation with a wavelength of 10.6 micrometers such that the maximum energy output of the laser does not exceed 9.8 × 10−3 joules per square centimeter (J/cm2);
( b ) The carbon dioxide laser shall be used only for etching information on the skin of fresh, intact citrus fruit, providing the fruit has been adequately washed and waxed prior to laser etching, and the etched area is immediately rewaxed after treatment; and
( c ) The maximum total energy to which the etched citrus fruit is exposed from the use of the carbon dioxide laser shall not exceed 1.5 × 10−3 J, and the maximum total etched surface area of the citrus fruit shall not exceed 0.122 cm2.
[77 FR 34215, June 11, 2012]
## 2013 D e c i sion s O p inion s of the U nit e d S t a t e s C our t of Appe al s for the Thir d C ir c uit

9-11-2013 

# U S A v . J o seph K onr a d

P r e c e de n t i al or N on-P r e c e de n t i al : P r e c e de n t i al D ock e t N o . 12-1393

F o l lo w thi s a nd a dd it ion al w ork s a t : h tt p://d i g it alc ommon s .l a w . v i l l a no v a . e du/thir dc ir c uit_2013

Thi s de c i sion i s br ou gh t t o y ou for f r e e a nd ope n a c c e s s b y the O p inion s of the U nit e d S t a t e s C our t of Appe al s for the Thir d C ir c uit a t V i l l a no v a U niv e r sit y S choo l of L a

w Di g it al R e posit or y

. It h as be e n a c c e pt e d for inclusion in 2013 D e c i sion s b y a n a uthor i z e d a dmini s tr a t or of V i l l a no v a U niv e r sit y S choo l of L a

w Di g it al R e posit or y

. F or mor e infor m a t ion, p le as e c on t a ct Be n j a min
. C a rl s on@l a

w . v i l l a no v a . e du

. 

## R e c omme nde d C it a t ion

" U SA v . J os e p h Konr a d " (2013). 2013 D e cisio n s . P ape r 150. h tt p://d i g it alc ommon s .l a

w . v i l l a no v a . e du/thir dc ir c uit_2013/150

## UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT No. 12

- 1393 UNITED STATES OF AMERICA

v. JOSEPH KONRAD,

Appellant
(E.D. Pa. No. 2

- 11

- cr - 00015

- 001)

ORDER It appears that the opinion and judgment entered on Sept ember 5, 2013 in the above appeal was entered prematurely. At the direction of the Court, the opinion and judgment are vacated and a new opinion and judgment will be entered at the appropriate time.
For the Court,

Marcia M. Wald ron, Clerk Date: September 11, 2013
T nh/ cc: All Counsel of Record
#### § 1250.41 Submittal of construction plans.

Plans for the construction or major reconstruction of sanitary equipment or facilities for such conveyances shall be submitted to the Commissioner of Food and Drugs for review of the conformity of such plans with the requirements of this subpart, except that submittal of plans shall not be required for any conveyance under reconstruction if the owner or operator thereof has made arrangements satisfactory to the Commissioner of Food and Drugs for inspections of such conveyances while under reconstruction for the purpose of determining conformity with those requirements.

[40 FR 5624, Feb. 6, 1975, as amended at 48 FR 11432, Mar. 18, 1983]
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 19 - 0 6 60 STATE OF MONTANA,

Plaintiff and Appellee, v. ALVIAN ERREVY MARQUEZ ,

Defendant and Appellant.

ORDER Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an ext ension of time to and including May 1 , 20 20 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

March 25 2020

03/25/2020

Case Number: DA 19-0660
§ 186.1093 Sulfamic acid. ( a ) Sulfamic acid (H3NO3S, CAS Reg. No. 5329-14-6) is a white crystalline solid manufactured from urea, sulfur trioxide, and sulfuric acid. It is soluble and highly ionized in water.
( b ) In accordance with § 186.1(b)(1), the ingredient is used as an indirect food ingredient with no limitations other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as an indirect human food ingredient is based upon the current good manufacturing practice of using this ingredient in the manufacture of paper and paperboard that contact food.
( c ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[47 FR 29954, July 9, 1982]
Argued and submitted September 30,

vacated and remanded November 10, 1999

#### STATE OF OREGON, *Respondent, v.*DANNY BLAKE STUART, *Appellant.*

(96-587; CA A100410)

989 P2d 480

Eric M. Cumfer argued the cause and filed the briefs for appellant.

Jonathan H. Fussner, Assistant Attorney General, argued the cause for respondent. With him on the brief were Hardy Myers, Attorney General, and Michael D. Reynolds, Solicitor General.

Before Edmonds, Presiding Judge, and Armstrong, Judge, and Warren, Senior Judge.

PER CURIAM

*170PER CURIAM

Defendant appeals from a judgment convicting him of assault in the second degree. ORS 163.175(1)(c). All of defendant’s assignment of errors, except one, were decided in a companion case. *See State v. Cook,*163 Or App 578, 989 P2d 474 (1999). Defendant’s remaining assignment of error does not merit discussion.

Judgment of conviction vacated; remanded for entry of judgment of conviction for lesser-included offense of third-degree assault.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial  information extracted from the Balance
Sheet and Statement of Operations as of and for the 26 weeks ended July 31, 1999
and is qualified in its entirety by reference to such  financial  statements  as
included in the Company's Quarterly Report on Form 10-Q.
</LEGEND>
<CIK>                                          0000813775
<NAME>                                         Factory 2-U Stores, Inc.
<MULTIPLIER>                                   1,000


<S>                                            <C>
<PERIOD-TYPE>                                  6-MOS
<FISCAL-YEAR-END>                              JAN-29-2000
<PERIOD-START>                                 MAY-2-1999
<PERIOD-END>                                   JUL-31-1999
<CASH>                                         5,869
<SECURITIES>                                   0
<RECEIVABLES>                                  0
<ALLOWANCES>                                   0
<INVENTORY>                                    45,408
<CURRENT-ASSETS>                               56,300
<PP&E>                                         36,763
<DEPRECIATION>                                 14,688
<TOTAL-ASSETS>                                 111,646
<CURRENT-LIABILITIES>                          65,658
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       122
<OTHER-SE>                                     29,747
<TOTAL-LIABILITY-AND-EQUITY>                   111,646
<SALES>                                        177,030
<TOTAL-REVENUES>                               177,030
<CGS>                                          114,380
<TOTAL-COSTS>                                  114,380
<OTHER-EXPENSES>                               58,829
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             1,202
<INCOME-PRETAX>                                2,619
<INCOME-TAX>                                   1,074
<INCOME-CONTINUING>                            1,545
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   1,545
<EPS-BASIC>                                  0.13
<EPS-DILUTED>                                  0.12




</TABLE>
EXHIBIT 11.1
                                                                  
                          FORCENERGY INC
                COMPUTATION OF EARNINGS PER SHARE
                (in thousands, except per share data)
                                  
                                               For the Year Ended
Primary Earnings Per Share                         December 31,
                                              --------------------
                                                1996         1995
                                              --------    ---------
Net Income (Loss)                             $ 11,278    $ (1,853)
Weighted Average Common and
 Common Equivalent Shares Outstanding           19,726       12,910
Primary Earnings Per Share                    $    .57    $    (.14)


                                               For the Year Ended
Fully Diluted Earnings Per Share                  December 31,
                                              --------------------
                                                1996        1995
                                              ---------   ---------
Net Income (Loss)                             $ 11,278    $ (1,853)
Effect of conversion of 7%
 Exchangeable Subordinated Notes on
 interest expense                                4,407       4,420
Tax effect related to interest expense          (1,642)     (1,658)

Net Income (Loss) as adjusted                 $ 14,043    $    909
Weighted Average Common and
 Common Equivalent Shares Outstanding           22,568      15,526
Fully Diluted Earnings Per Share              $    .62    $    .06


Weighted Average Shares Outstanding
   (Fully Diluted EPS)                                December 31,
                                               --------------------
                                                1996          1995
                                               ------        ------
Weighted Average Common and
 Common Equivalent Shares Outstanding          22,568<F1>    12,910
Other Potentially Dilutive Securities:
  Conversion of 7% Exchangeable
   Subordinated Notes                              --         2,616
                                               22,568        15,526
[FN]
<F1>
Fully  diluted weighted average shares outstanding calculation for
1996  assumes that the Exchangeable Notes conversion  into 2,343,047
shares of common stock and exercises of  options  to purchase
323,503 shares of common stock  occurred  on  January 1, 1996.
[/FN]
I 

118TH CONGRESS 

2D SESSION H. R. 7228 

To amend title 17, United States Code, to expand the copyright protection 

provided to architectural works to golf courses, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 5, 2024 

Mr. FITZPATRICK (for himself and Mr. PANETTA) introduced the following 

bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend title 17, United States Code, to expand the copyright protection provided to architectural works to golf 

courses, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Bolstering Intellectual 

5 Rights against Digital Infringement Enhancement Act’’ or 

6 the ‘‘BIRDIE Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7228 IH

1 SEC. 2. EXPANSION OF COPYRIGHT PROTECTION PRO2 VIDED TO ARCHITECTURAL WORKS TO GOLF 

3 COURSES. 

4 (a) DESIGN OF GOLF COURSES.—Section 101 of title 

5 17, United States Code, is amended in the matter related 

6 to the definition of ‘‘architectural work’’— 

7 (1) by striking ‘‘drawings.’’ and inserting 

8 ‘‘drawings, and the design of a course on which golf 

9 is played (except for any course on which mini golf, 

10 or other similar game, is played) as embodied in any 

11 tangible medium of expression, including an archi12 tectural plan or drawing’’; and 

13 (2) by striking ‘‘features.’’ and inserting ‘‘fea14 tures. In the case of a course on which golf is 

15 played, the work also includes any of the following 

16 that is part of the course: 

17 ‘‘(1) Landscaping. 

18 ‘‘(2) An irrigation system. 

19 ‘‘(3) A path. 

20 ‘‘(4) A golf green. 

21 ‘‘(5) A tee. 

22 ‘‘(6) A facility in which golf is practiced. 

23 ‘‘(7) A bunker. 

24 ‘‘(8) A lake. 

25 ‘‘(9) A topographic feature.’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7228 IH

1 (b) APPLICATION.—This Act, and the amendments 

2 made by this Act, shall apply to— 

3 (1) a work created on or after December 1, 

4 1990; and 

5 (2) a work that was unconstructed and em6 bodied in unpublished plans or drawings on Decem7 ber 1, 1990. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
§ 208.26 Exemptions and deferrals. ( a ) FDA on its own initiative, or in response to a written request from an applicant, may exempt or defer any Medication Guide content or format requirement, except those requirements in § 208.20 (a)(2) and (a)(6), on the basis that the requirement is inapplicable, unnecessary, or contrary to patients' best interests. Requests from applicants should be submitted to the director of the FDA division responsible for reviewing the marketing application for the drug product, or for a biological product, to the application division in the office with product responsibility.
( b ) If the licensed practitioner who prescribes a drug product subject to this part determines that it is not in a particular patient's best interest to receive a Medication Guide because of significant concerns about the effect of a Medication Guide, the licensed practitioner may direct that the Medication Guide not be provided to the particular patient. However, the authorized dispenser of a prescription drug product subject to this part shall provide a Medication Guide to any patient who requests information when the drug product is dispensed regardless of any such direction by the licensed practitioner.
#### § 357.110 Anthelmintic active ingredient.

The active ingredient of the product is pyrantel pamoate when used within the dosage limits established in § 357.150(d)(1).
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Series of Studies on Employment of Women in Various Defense Industries

              																								United States. Women's Bureau.						"Employment of Women in Army Supply Depots in 1943 : Women's Bureau Bulletin, No. 192-8" in *Series of Studies on Employment of Women in Various Defense Industries : Women's Bureau Bulletin, No. 192*			(1945).						https://fraser.stlouisfed.org/title/5465/item/539660, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 207.65 How can a waiver of the electronic submission requirement be obtained? ( a ) All information submitted under this part must be transmitted to FDA electronically in accordance with § 207.61(a) unless FDA has granted a request for waiver of this requirement prior to the date on which submission of such information is due. Submission of a request for waiver does not excuse timely compliance with the registration and listing requirements. FDA will grant a waiver request if FDA determines that the use of electronic means for submission of registration and listing information is not reasonable for the registrant making the waiver request.
( b ) Waiver requests under this section must be submitted in writing and must include the specific reasons why electronic submission is not reasonable for the registrant and a U.S. telephone number and mailing address where FDA can contact the registrant. All waiver requests must be sent to: SPL Coordinator, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Silver Spring, MD 20993.
( c ) If FDA grants the waiver request, FDA may limit its duration and will specify terms of the waiver and provide information on how to submit establishment registration, drug listings, other information, and updates, as applicable.
<PAGE>   1



                                  EXHIBIT 99.1

POPE & TALBOT, INC.

NEWS                                                         Contact: Maria Pope
                                                                  (503) 228-9161

RELEASE 97-10

For Immediate Release Thursday - January 22, 1998

POPE & TALBOT ANNOUNCES THE SALE OF ITS PRIVATE LABEL TISSUE BUSINESS

        PORTLAND, OR -- Pope & Talbot, Inc., announced today that it has entered
into a definitive agreement to sell its private label tissue business to an
investor group led by PLAINWELL, INC. for $147 million in cash and certain
assumed liabilities. Pope & Talbot's tissue business generated approximately
$136 million of revenues or 29 percent of the total Company revenue in 1997.
Consummation of the transaction is subject to Hart-Scott-Rodino review and other
customary closing conditions, including receipt by the buyer of financing.

        Peter T. Pope, Chairman and Chief Executive Officer of Pope & Talbot,
stated, "The sale of our tissue business, coupled with our proposed acquisition
of Harmac Pacific, Inc. is the key to the ongoing restructuring of Pope &
Talbot's asset base, away from consumer products, towards our core pulp and wood
products businesses. Pope & Talbot will emerge a more focused, financially
strengthened Company with favorable growth prospects and potential for
acquisitions in the future."

        Mr. Pope went on to say, "We at Pope & Talbot believe that from a
strategic perspective this is the appropriate time for us to sell the tissue
business." Pope & Talbot's first step in its ongoing restructuring away from
consumer-oriented businesses was completed in 1996 with the sale of its private
label diaper business.

        Peter J. Solomon Company Limited advised Pope & Talbot in this
transaction.

        Pope & Talbot, Inc. is a publicly held, Portland, Oregon-based fiber and
wood products Company traded on the New York and Pacific Stock Exchanges. Pope &
Talbot was founded in 1849 and has operations in the U.S. and Canada.




                                       ###